PROVENGE® FOR HORMONE-REFRACTORY PROSTATE CANCER
CancerConsultants.com, 08/11/2010
Among men with metastatic, hormone-refractory prostate cancer, the immunotherapy agent Provenge® (sipuleucel-T) improves survival by roughly four months. The findings from this Phase III study were recently published in The New England Journal of Medicine
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment